InventisBio (SH:688382) Xin Lang Cai Jing·2025-09-02 06:02Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 11, 2013. The company went public on July 25, 2022. Its main business involves the research, production, and sales of innovative drugs, with 100% of its revenue coming from technology licensing and cooperation [1]. Stock Performance - On September 2, Yifang Biotechnology's stock fell by 5.07%, closing at 39.88 CNY per share, with a trading volume of 424 million CNY and a turnover rate of 2.47%. The company's total market capitalization is 23.064 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Tongtai Fund has a significant position in Yifang Biotechnology. The Tongtai Health Theme Mixed A Fund (011002) held 37,200 shares in the second quarter, accounting for 5.42% of the fund's net asset value, making it the fourth-largest holding. The estimated floating loss for today is approximately 79,200 CNY [2]. Fund Performance - The Tongtai Health Theme Mixed A Fund (011002) was established on April 8, 2021, with a current scale of 6.1823 million CNY. Year-to-date, it has achieved a return of 58.54%, ranking 514 out of 8,184 in its category. Over the past year, it has returned 69.4%, ranking 1,288 out of 7,971. Since inception, it has incurred a loss of 34.95% [2]. Fund Manager Information - The fund managers for Tongtai Health Theme Mixed A are Ma Yi and Mai Jianpei. Ma Yi has a tenure of 11 years and 170 days, managing assets totaling 6.063 billion CNY, with the best return during his tenure being 41.66% and the worst being -0.61%. Mai Jianpei has been in the role for 114 days, managing 161 million CNY, with the best return of 40.5% and the worst of 8.55% during his tenure [2].